Question to the Department for Business, Energy and Industrial Strategy:

To ask the Secretary of State for Business, Energy and Industrial Strategy, how many contractual commitments the Government has made with pharmaceutical companies involving the transfer of covid-19 vaccine technology to UK based manufacturers; and if he will publish the terms and conditions of those contracts.

The Government has invested over £300 million in securing and scaling up the UK’s manufacturing capabilities to be able to respond to this pandemic. This has included:

• expanding the UK vaccine manufacturing footprint through investments in expanding and accelerating the Vaccine Manufacturing & Innovation Centre’s (VMIC) Harwell site which is being run as a not-for profit; and
• collaborating with the Cell and Gene Therapy Catapult (CGTC) to fund a state-of-the-art Manufacturing Innovation Centre in Braintree

The Government has step in rights during pandemics at both VMIC and CGTC Braintree.

In addition, the Government has partnered with industry – for example Wockhardt where we have secured fill and finish reservation in the UK to support our vaccine programme.

As a result of these investments, and ongoing support of the Vaccine Taskforce three of the UK's eight COVID-19 vaccines (Oxford/AstraZeneca, Novavax and Valneva) are being or will be manufactured in the UK. The Oxford/AstraZeneca vaccine is delivered through a majority UK supply chain. The contracts for supply agreements with these vaccine companies are available on the Contracts Finder website.